April 15, 2008 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leader in genomics-based drug discovery, presented data today describing the target of LX6171 and initial Phase 1 clinical results at the American Academy of Neurology in Chicago. LX6171 is an internally-developed compound under evaluation by the company as a potential treatment for cognitive disorders. LX6171, currently in Phase 2 clinical testing, is one of four programs in human clinical trials as part of Lexicon’s 10TO10 program......“LX6171 may have potential in a broad range of applications involving cognitive disorders, including Alzheimer’s disease, attention disorders, and developmental disorders.”... Lexicon Pharmaceuticals' Press Release -
